The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- End Stage Liver Disease
- Sponsor
- Washington University School of Medicine
- Enrollment
- 101
- Primary Endpoint
- Feasibility of a prehabilitation program.
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The primary outcome of this study is to demonstrate the feasibility of a prehabilitation program at Barnes Jewish Hospital for liver transplant candidates. Those patients who consent to participate in the study and are placed on the transplant list will be randomized into either the control or intervention group. The intervention group receives a personalized home exercise program along with weekly phone calls to provide coaching, mentoring and motivation. Data collected at baseline, post-transplant and, post-transplant follow up will be compared among the two study groups. The secondary outcomes include: normative data of functional measures for patients with end stage liver disease and to determine the effect size for future research on prehabilitation in the patient population.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Being evaluated for liver transplantation by Barnes Jewish Hospital medical team
Exclusion Criteria
- •Non-english speaking
- •Medical contraindications to exercise as determined by the medical team
Outcomes
Primary Outcomes
Feasibility of a prehabilitation program.
Time Frame: 2 Years
Feasibility will be measured by participation and outcome assessment measures.
Secondary Outcomes
- Normative data on 10 meter walk for patients with end stage liver disease.(Baseline)
- Normative data on Timed Up and Go for patients with end stage liver disease.(Baseline)
- Normative data on Modified Dynamic Gait Index for patients with end stage liver disease.(Baseline)
- Normative data on Five Time Sit to Stand for patients with end stage liver disease.(Baseline)
- Normative data on 6 Minute Walk Test for patients with end stage liver disease.(Baseline)